Results 61 to 70 of about 27,286 (132)

Recent Innovations in Lipid-lowering Therapies

Guoji laonian yixue zazhi
Dyslipidemia is a major risk factor for atherosclerotic cardiovascular diseases. Recent advancements in lipid-lowering therapies have seen progress with statins, cholesterol absorption inhibitors, PCSK9 inhibitors, and omega-3 fatty acids becoming widely
Xin Hu, Xiaoming Wang
doaj   +1 more source

Lipid-lowering drug targets influence inflammatory bowel disease through gut microbiota and inflammatory cytokines

Journal of Lipid Research
Patients with dyslipidemia are at higher risk for inflammatory bowel disease (IBD), yet the impact of lipid-lowering medications on IBD remains unclear.
Xin Huang, Qihang Li, Ping Guo, Weiming Gong, Ying Wang, Zhongshang Yuan   +5 more
doaj   +1 more source

The influence of angiopoietin-like protein 3 on macrophages polarization and its effect on the podocyte EMT in diabetic nephropathy. [PDF]

Front Immunol, 2023
Ma Y, Chen Y, Xu H, Du N.
europepmc   +1 more source

Elevated angiopoietin-like protein 3 serum levels in diabetic nephropathy patients and its association with renal function and lipid profile. [PDF]

BMC Nephrol, 2023
Azadi SM, Fadaei R, Omid-Shafaat R, Hosseini J, Moradi N.   +4 more
europepmc   +1 more source

Physiological roles and regulation of hepatic angiopoietin-like protein 3 in Japanese Black cattle (Bos taurus) during the fattening period. [PDF]

J Anim Sci, 2023
Shikida R, Kim M, Futohashi M, Nishihara K, Lee H, Suzuki Y, Baek Y, Masaki T, Ikuta K, Iwamoto E, Uemoto Y, Haga S, Terada F, Roh S.   +13 more
europepmc   +1 more source

Angiopoietin-like protein 3 is an indicator of prognosis in esophageal cancer patients. [PDF]

Int J Clin Exp Med, 2015
Angiopoietin-like protein 3 (ANGPTL3) plays an important role in angiogenesis. This study aimed to examine the protein expression of ANGPTL3, and to evaluate its clinical significance in esophageal cancer. ANGPTL3 expression was detected using immunohistochemistry in 98 pairs of esophageal cancer and adjacent non-cancerous tissues.
Zhu L, Jiang L, Wang W, Jia W, Liu F, Jiao X, Zhu X, Bao J, Yu H.   +8 more
europepmc   +2 more sources

The Citrus Flavonoid Nobiletin Downregulates Angiopoietin-like Protein 3 (ANGPTL3) Expression and Exhibits Lipid-Modulating Effects in Hepatic Cells and Adult Zebrafish Models. [PDF]

Int J Mol Sci, 2022
Lin CY, Chen PY, Hsu HJ, Gao WY, Wu MJ, Yen JH.   +5 more
europepmc   +1 more source

Recurrence After Atrial Fibrillation Ablation and Investigational Biomarkers of Cardiac Remodeling

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Recurrence after atrial fibrillation (AF) ablation remains common. We evaluated the association between recurrence and levels of biomarkers of cardiac remodeling, and their ability to improve recurrence prediction when added to a clinical ...
Majd A. El‐Harasis, Joseph A. Quintana, J. Roberto Martinez‐Parachini, Gregory G. Jackson, Bibin T. Varghese, Zachary T. Yoneda, Brittany S. Murphy, Diane M. Crawford, Kelsey Tomasek, Yan Ru Su, Quinn S. Wells, Dan M. Roden, Gregory F. Michaud, Pablo Saavedra, Juan Carlos Estrada, Travis D. Richardson, Arvindh N. Kanagasundram, Sharon T. Shen, Jay A. Montgomery, Christopher R. Ellis, George H. Crossley, Magdalena Eberl, Ludovic Gillet, Andre Ziegler, M. Benjamin Shoemaker   +24 more
doaj   +1 more source

Disruption of the angiopoietin-like system connects lipid homeostasis and hypothalamic dysfunction in ALS

BMC Medicine
Background Alterations in lipid metabolism are manifestations of amyotrophic lateral sclerosis (ALS) that contribute to the risk and rate of progression.
Sruthi Sankari Krishnamurthy, Adriana Zardini Buzatto, Caley Campkin, Hans-Peter Müller, Diana Wiesner, Jochen Weishaupt, Veronika Klose, Maximilian Wiesenfarth, Zeynep Elmas, Christine Herrmann, Özlem Parlak, Kornelia Günther, Rami Saad, Ulrike Weiland, Luc Dupuis, Albert Ludolph, Liang Li, Jan Kassubek, Johannes Dorst, Francesco Roselli   +19 more
doaj   +1 more source

A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease. [PDF]

J Nanobiotechnology, 2022
Hu X, Fan J, Ma Q, Han L, Cao Z, Xu C, Luan J, Jing G, Nan Y, Wu T, Zhang Y, Wang H, Zhang Y, Ju D.   +13 more
europepmc   +1 more source